Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
ViiV Healthcare presents new data demonstrating positive real-world impact of its innovative long-acting injectables for HIV at IAS 2025
Real-world and implementation data describe effectiveness of long-acting Vocabria + Rekambys (CAB+RPV LA) for HIV treatment.
Download (PDF - 304.2KB)GSK completes acquisition of efimosfermin, a potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)
GSK plc today announced the completion of its previously announced acquisition of efimosfermin alfa from Boston Pharmaceuticals
Download (PDF - 151.5KB)Price of world’s first malaria vaccine (RTS,S) for children in endemic countries to be reduced by more than half, to less than $5
Price reduction is commitment by Bharat Biotech made possible through partnership with GSK.
Download (PDF - 186.0KB)Linerixibat accepted for review by the European Medicines Agency for cholestatic pruritus in patients with primary biliary cholangitis (PBC)
Submission based on data from positive GLISTEN phase III trial
Download (PDF - 163.2KB)Japan’s Ministry of Health, Labour and Welfare accepts regulatory application to expand use of GSK’s RSV vaccine, Arexvy, in adults aged 18-49 at increased risk of severe RSV disease
If approved, GSK’s RSV vaccine would be the first available in Japan to help protect this group
Download (PDF - 232.0KB)GSK’s RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency to expand use in adults 18 years and older
Regulatory decision anticipated H1 2026.
Download (PDF - 191.1KB)GSK licenses Shigella vaccine candidate to Bharat Biotech for continued development
GSK plc announced today that it has licensed its Shigella vaccine candidate, altSonflex1-2-3, to Bharat Biotech International Limited.
Download (PDF - 196.8KB)Linerixibat New Drug Application (NDA) accepted for review by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC)
Application based on data from positive GLISTEN phase III trial
Download (PDF - 155.6KB)GSK data at ASCO and EHA showcase latest research and innovation across the oncology portfolio
GSK today announced that data across the oncology pipeline and portfolio will be presented at ASCO and EHA.
Download (PDF - 350.5KB)PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by Independent Data Monitoring Committee
Data to be part of a planned US FDA filing in H2 2025
Download (PDF - 134.4KB)Blenrep (belantamab mafodotin) combinations receive positive CHMP opinion in relapsed/refractory multiple myeloma
Positive opinion supported by superior efficacy shown in two head-to-head phase III trials, including overall survival in DREAMM-7.
Download (PDF - 253.6KB)Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)
Approval based on the positive MATINEE and METREX phase III trials
Download (PDF - 177.4KB)Blenrep (belantamab mafodotin) combinations approved in Japan for treatment of relapsed/refractory multiple myeloma
Second major approval for Blenrep combinations, with more expected in 2025
Download (PDF - 172.6KB)GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)
Affecting up to 5% of the global population, SLD represents an area of significant unmet medical need with limited treatment options.
Download (PDF - 212.7KB)GSK provides update on belrestotug development programme
GSK with its development partner iTeos Therapeutics, Inc., has confirmed it is ending the development programme for belrestotug.
Download (PDF - 110.2KB)GLISTEN phase III trial results show linerixibat significantly improves cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC)
Late-breaking results presented at the European Association for the Study of the Liver (EASL) Congress 2025
Download (PDF - 162.9KB)GSK continues to advance the future of respiratory medicine and patient care with new data at ATS
40+ abstracts across GSK’s inhaled and respiratory biologics portfolio
Download (PDF - 189.0KB)Nucala (mepolizumab) delivers clinically meaningful and statistically significant reduction in COPD exacerbations, with positive MATINEE trial results published in New England Journal of Medicine
21% reduction in annualised rate of moderate/severe exacerbations in a wide COPD population
Download (PDF - 185.7KB)GSK makes strong start to 2025 with growth in sales, profits and earnings
Q1 2025 performance highlights
Download (PDF - 780.9KB)Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple myeloma
Superior efficacy shown in two head-to-head phase III trials, including overall survival in DREAMM-7.
Download (PDF - 245.2KB)